Gilead Sciences Inc. (GILD)
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit
Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court documents alleged a twice-convicted medical fraudster wearing a court-ordered GPS ankle monitor was behind the scheme.
US FDA approves Gilead's liver disease drug
The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' drug for a chronic and potentially fatal liver disease that mostly affects women.
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.
Gilead Posts Solid Revenue in Q2
Revenue of $7.0 billion, up 6% excluding Veklury. Non-GAAP diluted EPS of $2.01.
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Gilead Sciences, Inc. (GILD) Q2 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Evan Seigerman - BMO Capital Markets Terence Flynn - Morgan Stanley Daina Graybosch - Leerink Partners Umer Raffat - Evercore ISI Carter Gould - Barclays Michael Yee - Jefferies Brian Abrahams - RBC Capital Markets Chris Schott - JPMorgan Steven Seedhouse - Raymond James Tim Anderson - Wolf Research Salveen Richter - Goldman Sachs Olivia Brayer - Cantor Fitzgerald Operator Good afternoon, everyone, and welcome to Gilead's Second Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today.
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $1.34 per share a year ago.
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
Gilead stock is nearing a breakout after the company reported better-than-expected second-quarter sales and profit.
